Vesicular monoamine transporters: Structure-function, pharmacology, and medicinal chemistry

Medicinal Research Reviews

Volumn 31, Issue 4, 2011, Pages 483-519

  Wimalasena, Kandatege ^a  

^a WICHITA STATE UNIVERSITY   (United States)

Author keywords

Catecholamine metabolism; Oxidative stress; Parkinson's disease; Psychostimulant abuse; Synaptic vesicles; Vesicular monoamine transporter 1 (VMAT1); Vesicular monoamine transporter 2 (VMAT2)

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMPHETAMINE; AMPHETAMINE DERIVATIVE; APOMORPHINE; CATECHOLAMINE; COCAINE; DIHYDROTETRABENAZINE; ETICLOPRIDE; HALOPERIDOL; KETANSERIN; LOBELINE; METHAMPHETAMINE; METHYLPHENIDATE; PHENETHYLAMINE; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; RADIOLIGAND; RESERPINE; TETRABENAZINE; VESICULAR ACETYLCHOLINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; CATECHOLAMINE METABOLISM; CENTRAL NERVOUS SYSTEM; CHOREA; CHROMAFFIN CELL; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG DEPENDENCE; EXTRAPYRAMIDAL SYMPTOM; GENE LOCUS; HUMAN; HUNTINGTON CHOREA; IMAGING; KNOCKOUT MOUSE; MONOAMINE NERVE CELL; MUTAGENESIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHOTOAFFINITY LABELING; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PROTEIN STRUCTURE; SCHIZOPHRENIA; SYNAPSE VESICLE; TISSUE DISTRIBUTION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY, PHARMACEUTICAL; HUMANS; KINETICS; LIGANDS; STRUCTURE-ACTIVITY RELATIONSHIP; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 79959573043     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20187     Document Type: Article

References (168)

1. Henry J-P, Sagne C, Bedet C, Gasnier B. The vesicular monoamine transporter: From chromaffin granule to brain. Neurochem Int 1998;32:227-246.
2. Schuldiner S, Shirvan A, Linial M. Vesicular neurotransmitter transporters: From bacteria to humans. Physiol Rev 1996;75:369-392.
3. Rudnick G. Bioenergetics of neurotransmitter transport. J Bioenerg Biomembr 1998;30:173-185.
4. Eiden LE, Schäfer MK, Weihe E, Schütz B. The vesicular amine transporter family (SLC18): Amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 2004;447:636-640.
5. Schuldiner S. A molecular glimpse of vesicular monoamine transporters. J Neurochem 1994;62:2067-2078.
6. Gasnier B. The loading of neurotransmitters into synaptic vesicles. Biochimie 2000;82:327-337.
7. Henry J-P, Botton D, Sagne C, Isambert MF, Desnos C, Blanchard V, Raisman-Vozari R, Krejci E, Massoulie J, Gasnier B. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J Exp Biol 1994;196:251-262.
8. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick C. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 1993;44:1227-1231.
9. Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 2007;101:883-888.
10. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Ann Rev Pharmacol Toxicol 2007;47:681-698.
11. Daniels AJ, Reinhard JF, Jr. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 1988;263:5034-5036.
12. Darchen F, Scherman D, Henry JP. Characteristics of the transport of quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules. Biochem Pharmacol 1988;37:4381-4387.
13. Lotharius J, O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 2000;275:38581-38588.
14. German DC, Sonsalla PK. A role for the vesicular monoamine transporter (VMAT2) in Parkinson's disease. Adv Behav Biol 2003;54:131-137.
15. + toxicity encodes a vesicular amine transporter. Cell 1992;70:539-551.
16. Erickson JD, Eiden LE. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem 1993;61:2314-2317.
17. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 1992;89:10993-10997.
18. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. Differential expression of two vesicular monoamine transporters. J Neurosci 1995;15:6179-6188.
19. Weihe E, Schafer MKH, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT-1 and VMAT-2) to endocrine cells and neurons in rat. J Mol Neurosci 1995;5:149-164.
20. Erickson JD, Schafer MKH, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996;93:5166-5171.
21. Hansson SR, Mezey E, Hoffman BJ. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. II. Expression in neural crest derivatives and their target sites in the rat. Brain Res Dev Brain Res 1998;110:159-174.
22. Howell M, Shirvan A, Stern-Bach Y, Steiner-Mordoch S, Strasser JE, Dean GE, Schuldiner S. Cloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules. FEBS Lett 1994;338:16-22.
23. Krejci E, Gasnier B, Botton D, Isambert MF, Sagné C, Gagnon J, Massoulié J, Henry JP. Expression and regulation of the bovine vesicular monoamine transporter gene. FEBS Lett 1993;335:27-32.
24. Parsons SM. Transport mechanisms in acetylcholine and monoamine storage. FASEB J 2000;14:2423-2434.
25. Bravo D, Parsons SM. Microscopic kinetics and structure-function analysis in the vesicular acetylcholine transporter. Neurochem Int 2002;41:285-289.
26. Hofmann K, Stoffel WA. Database of membrane spanning proteins segments. Biol Chem Hoppe-Seyler 1993;374:166.
27. Njus D, Kelley PM, Harnadek GJ. Bioenergetics of secretory vesicles. Biochim Biophys Acta 1986;853:237-265.
28. Kirshner N. Uptake of catecholamines by a particulate fraction of the adrenal medulla. J Biol Chem 1962;237:2311-2317.
29. +-linked dopamine transport in chromaffin granule ghosts. Biochemistry 1981;20:6625-6629.
30. Darchen F, Scherman D, Henry JP. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 1989;28:1692-1697.
31. Henry JP, Sagné C, Botton D, Isambert MF, Gasnier B. Molecular pharmacology of the vesicular monoamine transporter. Adv Pharmacol 1998;42:236-239.
32. Knoth J, Isaacs JM, Njus D. Amine transport in chromaffin granule ghosts. pH dependence implies cationic form is translocated. J Biol Chem 1981;256:6541-6543.
33. Wimalasena DS, Wimalasena K. Kinetic evidence for channeling of dopamine between monoamine transporter and membranous dopamine-beta-monooxygenase in chromaffin granule ghosts. J Biol Chem. 2004;279:15298-15304.
34. Scherman D, Jaudon P, Henry JP. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad Sci USA 1983;80:584-588.
35. Scherman D, Henry JP. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol Pharmacol 1984;25:113-122.
36. Darchen F, Scherman D, Laduron PM, Henry JP. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol 1988;33:672-677.
37. 3H]serotonin in preparations from whole brain and brain regions. J Neurochem 1978;31:961-968.
38. Disbrow JK, Ruth JA. Greatly extended viability of rat brain storage vesicles in an intracellular medium based upon a non-permeant polyanion. Life Sci 1981;29:1989-1996.
39. Pothos EN, Larsen KE, Krantz DE, Liu Y, Haycock JW, Setlik W, Gershon MD, Edwards RH, Sulzer D. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 2000;20:7297-7306.
40. Sulzer D, Pothos EN. Regulation of quantal size by presynaptic mechanisms. Rev Neurosci 2000;11:159-212.
41. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem 1994;269:7231-7237.
42. Gasnier B, Krejci E, Botton D, Massoulie J, Henry JP. Expression of a bovine vesicular monoamine transporter in COS cells. FEBS Lett 1994;342:225-229.
43. Shirvan A, Laskar O, Steiner-Mordoch S, Schuldiner S. Histidine-419 plays a role in energy coupling in the vesicular monoamine transporter from rat. FEBS Lett 1994;356:145-150.
44. Steiner-Mordoch S, Shirvan A, Schuldiner S. Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate. J Biol Chem 1996;271:13048-13054.
45. Merickel A, Kaback HR, Edwards RH. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J Biol Chem 1997;272:5403-5408.
46. Finn III JP, Edwards RH. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. J Biol Chem 1997;272:16301-16307.
47. Finn III JP, Edwards RH. Multiple residues contribute independently to differences in ligand recognition between vesicular monoamine transporters 1 and 2. J Biol Chem 1998;273:3943-3947.
48. Thiriot DS, Ruoho AE. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J Biol Chem 2001;276:27304-27315.
49. Thiriot DS, Sievert MK, Ruoho AE. Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond. Biochemistry 2002;41:6346-6353.
50. Sagne C, Isambert MF, Vandekerckhove J, Henry JP, Gasnier B. The photoactivatable inhibitor 7-azido-8-iodoketanserin labels the N terminus of the vesicular monoamine transporter from bovine chromaffin granules. Biochemistry 1997;36:3345-3352.
51. 125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J Biol Chem 1997;272:26049-26055.
52. Gopalakrishnan A, Sievert M, Ruoho AE. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe. Mol Pharmacol 2007;72:1567-1575.
53. Perera RP, Wimalasena DS, Wimalasena K. Characterization of a series of 3-amino-2-phenylpropene derivatives as novel bovine chromaffin vesicular monoamine transporter inhibitors. J Med Chem 2003;46:2599-2605.
54. Moriyama Y, Amakatsu K, Futai M. Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: A proton gradient drives its uptake through monoamine transporter. Arch Biochem Biophy 1993;305:271-277.
55. + derivatives: A structure-activity study. J Med Chem 2008;51:760-768.
56. Chaplin L, Cohen AH, Huettl P, Kennedy M, Njus D, Temperley SJ. Reserpic acid as an inhibitor of norepinephrine transport into chromaffin vesicle ghosts. J Biol Chem 1985;260:10981-10985.
57. 3H]dopamine from rat striatal synaptic vesicles: Comparison with d-amphetamine. J Neurochem 1998;71:258-265.
58. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther 2004;310:1035-1045.
59. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. Defunctionalized lobeline analogues: Structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem 2005;48:5551-5560.
60. Haikerwal D, Dart AM, Little PJ, Kaye DM. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport. J Pharmacol Exp Ther 1999;288:834-837.
61. Efange SMN. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J 2000;14:2401-2413.
62. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol 2001;86:237-247.
63. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 2005;11:3237-3245.
64. Maffei A, Harris PE. Targeting vesicular monoamine transporter type 2 for noninvasive PET-based β-cell mass measurements. Expert Rev Endocrinol Metab 2007;2:35-46.
65. 11C]tetrabenazine to vesicular monoamine transporters in mouse brain. Life Sci 1992;51:593-600.
66. 11C]tetrabenazine and positron emission tomography. J Neurochem 1993;60:2315-2318.
67. 11C]tetrabenazine. Synapse 1993;14:128-131.
68. 11C]Tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl Med Biol 1994;21:151-156.
69. Gilman S, Frey KA, Koeppe RA, Junck L, Little R, Vander Borght TM, Lohman M, Martorello S, Lee LC, Jewett DM, Kilbourn MR. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol 1996;40:885-892.
70. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
71. 11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997;17:919-931.
72. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA. Positron emission tomography of monoaminergic vesicular binding in aging and parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
73. 11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008;62:873-876.
74. 11C]-dihydrotetrabenazine imaging of baboons: Biodistribution and human radiation dosimetry estimates. Eur J Nucl Med Mol Imaging 2008;35:790-797.
75. 3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988;50:1131-1136.
76. Lehericy S, Brandel JP, Hirsch EC, Anglade P, Villares J, Scherman D, Duyckaerts C, Javoy-Agid F, Agid Y. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res 1994;659:1-9.
77. 3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68:955-962.
78. Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, Frey KA. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995;36:2252-2260.
79. Kilbourn MR, Frey KA, Borght TV, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996;23:467-471.
80. 11C]MTBZ) in tottering mice. Nucl Med Biol 1995;22:565-567.
81. Canney DJ, Guo YZ, Kung MP, Kung HF. Synthesis and preliminary evaluation of an iodovinyl-tetrabenazine analog as a marker for the vesicular monoamine transporter. J Labelled Compd Radiopharm 1993;33:355-368.
82. 11C]methoxy derivative of alpha-dihydrotetrabenazine: A radioligand for studying the vesicular monoamine transporter. Appl Radiat Isot 1993;44:1487-1489.
83. Saner A, Pletscher A. A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover. J Pharmacol Exp Ther 1977;203:556-563.
84. 125I-iodovinyltetrabenazine to CNS vesicular monoamine transportsites. Synapse 1994;18:225-232.
85. Lee LC, Vander Borght T, Sherman PS, Frey KA, Kilbourn MR. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter. J Med Chem 1996;39:191-196.
86. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 2006;33:685-694.
87. 18F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biology 2007;34:233-237.
88. Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007;34:239-246.
89. 11C]DTBZ. Nucl Med Biol 2006;33:855-864.
90. Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, Skovronsky D, Kilbourn MR, Kung HF. In vivo imaging of β-cell mass in rats using 18F-FP-(+)-DTBZ: A potential PET ligand for studying diabetes mellitus. J Nucl Med 2008;49:1171-1176.
91. Kung HF, Lieberman BP, Zhuang ZP, Oya S, Kung MP, Choi SR, Poessl K, Blankemeyer E, Hou C, Skovronsky D, Kilbourn MR. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Nucl Med Biol 2008;35:825-837.
92. 125I]iodoketanserin. Neuroscience 1989;33:341-349.
93. 125I]iodoketanserin. Biochemistry 1989;28:2265-2270.
94. Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 2000;74:2221-2223.
95. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: Mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 2002;300:1093-1100.
96. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 2001;296:762-767.
97. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 2003;304:1181-1187.
98. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 2002;449:71-74.
99. Brown JM, Hanson GR, Fleckenstein AE. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J Pharmacol Exp Ther 2001;298:1150-1153.
100. Fleckenstein AE, Brown JM, Sandoval V, Riddle EL, Hansen JP, Ugarte YV, Gibb JW, Hanson GR. D2 receptor-mediated regulation of vesicular dopamine uptake. Adv Behav Biol 2002;53:39-42.
101. Ugarte YV, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors. Eur J Pharmacol 2003;472:165-171.
102. Eyerman DJ, Yamamoto BK. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 2007;103:1219-1227.
103. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med 1996;2:699-703.
104. Kitamura O, Tokunaga I, Gotohda T, Kubo S. Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 2007;121:163-168.
105. Frey K, Kilbourn MR, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 1997;334:273-279.
106. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK. Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization. Psychopharmacology 2005;180:501-512.
107. Lu W, Wolf ME. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration. Mol Brain Res 1997;49:137-148.
108. Schwartz K, Nachman R, Yossifoff M, Sapir R, Weizman A, Rehavi M. Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2. J Neural Transm 2007;114:427-430.
109. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996;40:428-439.
110. Little KY, Krolewski DM, Zhang L, Cassin BJ. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiat 2003;160:47-55.
111. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997;19:1271-1283.
112. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997;19:1285-1296.
113. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 1999;19:2424-2431.
114. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94:9938-9943.
115. Sulzer D, Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 1990;5:797-808.
116. Schwartz K, Weizman A, Rehavi M. The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles. J Neural Transm 2006;113:1347-1352.
117. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 2006;319:237-246.
118. Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 2000;74:2221-2223.
119. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 2002;449:71-74.
120. Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A. Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux. J Neurochem 2006;96:1149-1159.
121. Cohen G, Kesler N. Monoamine oxidase and mitochondrial respiration. J Neurochem 1999;73:2310-2315.
122. Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 1997;20:125-156.
123. Adams JD, Jr, Chang ML, Klaidman L. Parkinson's disease-redox mechanisms. Curr Med Chem 2001;8:809-814.
124. Samms WC, Perera RP, Wimalasena DS, Wimalasena K. Perturbation of dopamine metabolism by 3-amino-2-(4'-halophenyl)propenes leads to increased oxidative stress and apoptotic SH-SY5Y cell death. Mol Pharmacol 2007;72:744-752.
125. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
126. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. Primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
127. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-467.
128. Heikkila RE, Manzino L, Cabbot FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
129. Langston JW, Irwin I, Langston EB. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.
130. Bradbury AJ, Costall B, Domeney AM, Jenner P, Kelly ME, Marsden CD, Naylor RJ. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 1986;319:56-57.
131. Bové J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-494.
132. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6 -tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177.
133. Storch A, Ludolph AC, Schwarz J. Dopamine transporter: Involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004;111:1267-1286.
134. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter. J Neurochem 1997;69:1322-1325.
135. Reinhard JF, Jr, Diliberto EJ, Jr, Viveros OH, Daniels AJ. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 1987;84:8160-8164.
136. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci 1985;36:2503-2508.
137. +. Biochem Biophys Res Commun 1986;134:743-748.
138. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-895.
139. Fornai F, Schlüter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof TC. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005;102:3413-3418.
140. Wimalasena K, Le V. Unpublished observations.
141. +, or paraquat. Proc Natl Acad Sci USA 2008;105:15136-15141.
142. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 2002;109:1159-1180.
143. Wang J, Xu Z, Fang H, Duhart HM, Patterson TA, Ali SF. Gene expression profiling of MPP(+)-treated MN9D cells: A mechanism of toxicity. Neurotoxicology 2007;28:979-987.
144. +-treated PC12 Cells: Mechanisms of toxicity (MOT) analysis using bioinformatics tools BMC. Bioinformatics 2005;6:S8.
145. Zheng G, Dwoskin LP, Crooks PA. Vesicular monoamine transporter 2: Role as a novel target for drug development. AAPS J 2006;8:E682-E692.
146. Auriel E, Hausdorff JM, Giladi N. Methylphenidate for the treatment of Parkinson disease and other neurological disorders. Clin Neuropharmacol 2009;32:75-81.
147. Truong JG, Rau KS, Hanson GR, Fleckenstein AE. Pramipexole increases vesicular dopamine uptake: Implications for treatment of Parkinson's neurodegeneration. Eur J Pharmacol 2003;474:223-226.
148. Truong JG, Hanson GR, Fleckenstein AE. Apomorphine increases vesicular monoamine transporter-2 function: Implications for neurodegeneration. Eur J Pharmacol 2004:492:143-147.
149. Grimbergen YA, Roos RA. Therapeutic options for Huntington's disease. Curr Opin Investig Drugs 2003;4:51-54.
150. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109.
151. Dalby MA. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J 1969;2:422-423.
152. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-302.
153. Marshall FJ, Walker F, Frank S, Oakes D, Plumb S, Factor SA, Fahn S, Hunt VP, Jankovic J, Shinaman A, Shoulson I. Tetrabenazine as antichorea therapy in Huntington's disease: A randomized controlled trial. Neurology 2006;66:366-372.
154. Food and Drug Administration. FDA labeling information. FDA web site (online)
155. Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 2002;63:89-98.
156. Xie Y, Raffo A, Ichise M, Deng S, Harris PE, Landry DW. Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists. Bioorg Med Chem Lett 2008;18:5111-5114.
157. Harris P, Xie Y, Landry D, Deng SX, Maffei A. Methods and compositions using a vesicular monoamine transporter type 2 (VMAT2) antagonist for modulating insulin secretion and glucose metabolism. PCT Int. Appl. 2008; Application: WO 2008-US3338 20080312.
158. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 2006;15:299-305.
159. Schwab SG, Franke PE, Hoefgen B, Guttenthaler V, Lichtermann D, Trixler M, Knapp M, Maier W, Wildenauer DB. Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence. Neuropsychopharmacology 2005;30:2263-2268.
160. Lin Z, Walther D, Yu XY, Li S, Drgon T, Uhl GR. SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 2005;14:1393-1404.
161. Schwartz K, Yadid G, Weizman A, Rehavi M. Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression. Brain Res 2003;965:174-179.
162. Bly M. Mutation in the vesicular monoamine gene, SLC18A1, associated with Shizophrenia. Schizophr Res 2005;78:337-338.
163. Richards M, Iijima Y, Kondo H, Shizuno T, Hori H, Arima K, Saitoh O, Kunugi H. Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav Brain Funct 2006;2:39.
164. Lohoff FW, Weller AE, Bloch PJ, Buono RJ, Doyle GA, Ferraro TN, Berrettini WH. Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia. Neuropsychobiology 2008;57:55-60.
165. Lohoff FW, Dahl JP, Ferraro TN, Arnold SE, Gallinat J, Sander T, Berrettini WH. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder. Neuropsychopharmacology 2006;31:2739-2747.
166. Lohoff FW, Lautenschlager M, Mohr J, Ferraro TN, Sander T, Gallinat J. Association between variation in the vesicular monoamine transporter 1 gene on chromosome 8p and anxiety-related personality traits. Neurosci Lett 2008;434:41-45.
167. Gutierrez B, Rosa A, Papiol S, Arrufat FJ, Catalan R, Salgado P, Peralta V, Cuesta MJ, Fananas L. Identification of two risk haplotypes for schizophrenia and bipolar disorder in the synaptic vesicle monoamine transporter gene (SVMT). Am J Med Genet B Neuropsychiatr Genet 2007;144B:502-507.
168. Zheng G, Dwoskin LP, Deaciuc AG, Zhu J, Jones MD, Crooks PA. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem 2005;13:3899-3909.